Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $21.00 price target on the stock.
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival [Yahoo! Finance]
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]